keyword
MENU ▼
Read by QxMD icon Read
search

second-line

keyword
https://www.readbyqxmd.com/read/28103447/pharmacotherapy-for-treating-metastatic-clear-cell-renal-cell-carcinoma
#1
Camillo Porta, Silvia Chiellino, Alessandra Ferrari, Sara Mariucci, Wanda Liguigli
Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far...
January 19, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28101487/immunoglobulin-g4-related-thyroid-diseases
#2
REVIEW
Dulani Kottahachchi, Duncan J Topliss
Immunoglobulin G4-related disease (IgG4-RD) is a new disease category involving many organ systems, including the endocrine system in general and the thyroid in particular. Since an initial association was made between hypothyroidism and autoimmune (IgG4-related) pancreatitis, more forms of IgG4-related thyroid disease (IgG4-RTD) have been recognized. Four subcategories of IgG4-RTD have so far been identified: Riedel thyroiditis (RT), fibrosing variant of Hashimoto thyroiditis (FVHT), IgG4-related Hashimoto thyroiditis, and Graves disease with elevated IgG4 levels...
December 2016: European Thyroid Journal
https://www.readbyqxmd.com/read/28100602/find-tuberculosis-strain-bank-a-resource-for-researchers-and-developers-working-on-tests-to-detect-mycobacterium-tuberculosis-and-related-drug-resistance
#3
Belay Tessema, Pamela Nabeta, Eloise Valli, Audrey Albertini, Jimena Collantes, Nguyen Huu Lan, Elena Romancenco, Nestani Tukavdze, Claudia M Denkinger, David L Dolinger
BACKGROUND: The spread of multidrug-resistant tuberculosis and extensively drug-resistant TB hampers the global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well characterized strains and samples from drug resistant tuberculosis patients are necessary. In this project, FIND has focused on the collection, characterization and storage of such well-characterized reference materials and to make them available to researchers and developers...
January 18, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28099901/efficacy-of-sequential-therapies-with-sorafenib-sunitinib-versus-sunitinib-sorafenib-in-metastatic-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#4
REVIEW
Tingyu Wen, Hai Xiao, Chao Luo, Li Huang, Meimei Xiong
The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial and not answered clearly until now. This meta-analysis aims to estimate the efficacy of receptor tyrosine kinase inhibitors sorafenib-sunitinib and sunitinib-sorafenib for metastatic renal cell carcinoma, on the outcome of first-line progression-free survival, second-line progression-free survival, total progression-free survival and overall survival...
January 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28099228/transitioning-to-second-line-antiretroviral-therapy-among-adolescents-in-copperbelt-province-zambia-predictors-of-treatment-switching-and-adherence-to-second-line-regimens
#5
Randy M Stalter, Patrick Katayamoyo, Catherine Packer, Harry Banda, Pai-Lien Chen, Jonathan K Mwansa, Donna R McCarraher, Julie A Denison
BACKGROUND: Adolescents living with HIV (ALHIV) experience less favorable antiretroviral therapy (ART) outcomes than other age groups. First-line treatment failure complicates ART management as second-line regimens can be costlier and have greater pill burdens. Understanding predictors of switching ART regimens and adherence among adolescents on second-line ART may help to prevent poor treatment outcomes. METHODS: A quantitative survey was administered to 309 ALHIV attending three ART clinics in the Copperbelt Province, Zambia...
January 16, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28098864/victor-vinflunine-in-advanced-metastatic-transitional-cell-carcinoma-of-the-urothelium-a-retrospective-analysis-of-the-use-of-vinflunine-in-multi-centre-real-life-setting-as-second-line-chemotherapy-through-free-of-charge-programme-for-patients-in-the-uk-and
#6
Syed A Hussain, Jawaher Ansari, Robert Huddart, Derek G Power, Jeanette Lyons, James Wylie, Maria Vilarino-Varlela, Nils O Elander, Rhona McMenemin, Lisa M Pickering, Guy Faust, Seema Chauhan, Richard J Jackson
There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care in Europe but is not routinely available in the UK. Data were collected retrospectively on patients who received vinfluine as a second-line treatment. The aims were to document the toxicity and efficacy in a real life setting. Data were collected on 49 patients from 9 sites across the UK and Ireland [median age, 64 (IQR, 57-70) years, 33 males]...
January 13, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28097046/molecular-classification-of-tissue-from-a-transformed-non-hogkin-s-lymphoma-case-with-unexpected-long-time-remission
#7
Julie Støve Bødker, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Rasmus Froberg Brøndum, Maria Bach Laursen, Steffen Falgreen, Mette Nyegaard, Alexander Schmitz, Lasse Hjort Jakobsen, Anna Amanda Schönherz, Hanne Due, Linn Reinholdt, Martin Bøgsted, Karen Dybkær, Hans Erik Johnsen
BACKGROUND: The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing and global gene expression in a patient with unexpected long-term remission following relaps. The goals were to phenotype the diagnostic and relapsed lymphoma tissue and evaluate its pattern. Furthermore, to identify mutations available for targeted therapy and expression of genes to predict specific drug effects by resistance gene signatures (REGS) for R-CHOP as described at http://www...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/28096987/therapeutic-plasma-exchange-a-second-line-treatment-for-brodifacoum-poisoning-following-an-anaphylactoid-reaction-to-vitamin-k
#8
Ying Deng, Li Qiu
Vitamin K1 is the first-line therapy to brodifacoum poisoning. Anaphylactoid reactions may occur anytime during intravenous administration of vitamin K1 injection. Vitamin K1 must be ceased when anaphylactoid reactions emerge, and therapeutic plasma exchange could be a second-line option.
January 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28096936/treatment-options-in-advanced-renal-cell-carcinoma-after-first-line-treatment-with-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors
#9
REVIEW
Naveen S Basappa
Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago and since then, a number of therapeutic options have been developed. Vascular endothelial growth factor-targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the second-line setting has typically been with either axitinib or everolimus. However, with the advent of several new agents demonstrating efficacy in the second-line setting, including nivolumab, cabozantinib, and the combination of lenvatinib and everolimus, the treatment paradigm has shifted toward these novel therapies with improved patient outcomes...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28095920/accuracy-of-who-immunological-criteria-in-identifying-virological-failure-among-hiv-infected-adults-on-first-line-antiretroviral-therapy-in-mwanza-north-western-tanzania
#10
Daniel W Gunda, Benson R Kidenya, Stephen E Mshana, Semvua B Kilonzo, Bonaventura C T Mpondo
BACKGROUND: Optimal HIV treatment monitoring remains a big challenge in resource limited settings. Guidelines recommend the use of clinical and immunological criteria in resource limited settings due to unavailability of viral load monitoring; however their utility is questionable. This study aimed at assessing the accuracy of immunological criteria in detecting treatment failure among HIV infected Tanzanian adults receiving first line ART. METHODS: A clinic based cross sectional study was conducted between February and July 2011 at Bugando Medical centre (BMC) HIV care and treatment clinic (CTC) involving HIV infected patients aged 18 years and above, receiving first line ART; followed up for at least 1 year...
January 17, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#11
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28094573/advanced-gastric-adenocarcinoma-optimizing-therapy-options
#12
Dilsa Mizrak Kaya, Kazuto Harada, Yusuke Shimodaira, Fatemeh G Amlashi, Quan Lin, Jaffer A Ajani
Gastric adenocarcinoma (GAC) is the fifth most common cancer and third leading cause of cancer related mortality worldwide. When localized, cure is achievable with surgery and adjunctive therapies in some patients, however, once advanced, GAC is not a curable condition. Only two targeted agents (trastuzumab and ramucirumab) have been approved and apatinib was approved only in China. Because of the heterogeneous nature of GAC, it is not possible to assess a standard therapeutic approach. Areas Covered: In this review, we aimed to describe the optimal systemic therapy regimens for advanced GAC...
January 17, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28094071/on-nephrectomy-for-treating-metastatic-renal-cell-carcinoma
#13
C González-Ruiz de León, P Pellejero-Pérez, A Quintás-Blanco, J García-Rodríguez, C Álvarez-Fernández, J M Fernández-Gómez
INTRODUCTION: Systemic treatment for metastatic renal cell carcinoma (mRCC) has changed with the new therapies, and it is not clear if nephrectomy (NEP) has a survival benefit in this kind of patients. OBJECTIVE: To investigate if NEP associated to systemic treatment improves overall survival (OS) and progression-free survival (PFS). MATERIAL AND METHODS: A retrospective, observational, descriptive study of 45 patients with diagnosis of mRCC between 2006-2014...
January 13, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28094039/cisplatin-can-be-safely-administered-to-ovarian-cancer-patients-with-hypersensitivity-to-carboplatin
#14
A Bergamini, C Pisano, M Di Napoli, L Arenare, C Della Pepa, R Tambaro, G Facchini, P Gargiulo, S Rossetti, G Mangili, S Pignata, S C Cecere
OBJECTIVE: Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28093662/a-cost-effectiveness-analysis-of-lisdexamfetamine-dimesylate-in-the-treatment-of-adults-with-attention-deficit-hyperactivity-disorder-in-the-uk
#15
Evelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, Josephine A Mauskopf
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effectiveness of LDX as a first- or second-line treatment for adults with ADHD from the United Kingdom (UK) National Health Service (NHS) perspective compared with methylphenidate extended release (MPH-ER) and atomoxetine (ATX)...
January 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28093003/outcome-for-patients-with-relapsed-refractory-aggressive-lymphoma-treated-with-gemcitabine-and-oxaliplatin-with-or-without-rituximab-a-retrospective-multicentre-study
#16
Vijay Dhanapal, Menaka Gunasekara, Chia Lianwea, Robert Marcus, Corinne De Lord, Stella Bowcock, Stephen Devereux, Piers Patten, Deborah Yallop, David Wrench, Paul Fields, Shireen Kassam
The treatment of relapsed aggressive lymphoma remains a challenge. Platinum-containing chemotherapy is standard of care. Gemcitabine/oxaliplatin (Gem-Ox) with or without rituximab (R) is an outpatient regimen with a favorable toxicity profile. This retrospective 'real world' study reports outcomes for 44 unselected patients with relapsed/refractory aggressive lymphoma treated with Gem-Ox ± R. 41% had primary refractory disease. The overall response rate (ORR) was 43% with a complete response (CR) of 30%...
January 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28090683/similar-but-not-consistent-revisiting-the-pitfalls-of-measuring-igg-subclasses-with-different-assays
#17
Beatrice Ludwig-Kraus, Frank Bernhard Kraus
BACKGROUND: Laboratory quantification of IgG subclasses (IgGSc) is a well-established second-line tool for differential diagnosis of immune deficiencies. However, so far there is still no internationally approved standard available for IgGSc, and different assays are prone to produce divergent results. In this study, we evaluated the comparability and equivalence of two commercially available IgGSc assays, one being the Siemens IgGSc assay on a BN ProSpec analyzer and the other being The Binding Site (TBS) IgGSc assay on a Roche cobas c502 analyzer...
January 16, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28089478/the-clinical-course-of-minimal-change-nephrotic-syndrome-with-onset-in-adulthood-or-late-adolescence-a-case-series
#18
Rutger J Maas, Jeroen K Deegens, Johan R Beukhof, Louis J Reichert, Marc A Ten Dam, Jaap J Beutler, A Warmold L van den Wall Bake, Pieter L Rensma, Constantijn J Konings, Daniel A Geerse, Geert W Feith, Willi H Van Kuijk, Jack F Wetzels
BACKGROUND: Few studies have examined the treatment and outcome of adult-onset minimal change nephrotic syndrome (MCNS). We retrospectively studied 125 patients who had MCNS with onset in either adulthood or late adolescence. Presenting characteristics, duration of initial treatment and response to treatment, relapse patterns, complications, and long-term outcome were studied. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Patients with new-onset nephrotic syndrome 16 years or older and a histologic diagnosis of MCNS in 1985 to 2011 were identified from pathology records of 10 participating centers...
January 12, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28089216/diabetes-is-associated-with-severe-adverse-events-in-multidrug-resistant-tuberculosis
#19
Marcela Muñoz-Torrico, José Caminero-Luna, Giovanni Battista Migliori, Lia D'Ambrosio, José Luis Carrillo-Alduenda, Héctor Villareal-Velarde, Alfredo Torres-Cruz, Héctor Flores-Vergara, Dina Martínez-Mendoza, Cecilia García-Sancho, Rosella Centis, Miguel Ángel Salazar-Lezama, Rogelio Pérez-Padilla
INTRODUCTION: Diabetes mellitus (DM), a very common disease in Mexico, is a well-known risk factor for tuberculosis (TB). However, it is not known by which extent DM predisposes to adverse events (AE) to anti-TB drugs and/or to worse outcomes in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). The main objective of this study was to describe the outcomes of TB treatment, the impact of DM and the prevalence of AE in a cohort of patients with MDR-/XDR pulmonary TB treated at the national TB referral centre in Mexico City...
January 11, 2017: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/28088771/do-we-still-need-cross-sectional-studies-in-nephrology-yes-we-do
#20
Giovanni Tripepi, Graziella D'Arrigo, Kitty J Jager, Vianda S Stel, Friedo W Dekker, Carmine Zoccali
Cross-sectional studies represent the second line of evidence (after case reports) in the ladder of evidence aimed at defining disease aetiology. This study design is used to generate hypotheses about the determinants of a given disease but also to investigate the accuracy of diagnostic tests and to assess the burden of a given disease in a population. The intrinsic limitation of cross-sectional studies, when applied to generate aetiological hypotheses, is that both the exposure under investigation and the disease of interest are measured at the same point in time...
January 14, 2017: Nephrology, Dialysis, Transplantation
keyword
keyword
114245
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"